Management of Stage 2 Hypertension, Dyslipidemia, and Alcoholic Fatty Liver Disease in Young Adults

Alcohol Cessation

• Complete abstinence from alcohol is required in patients with active alcoholic hepatitis, as indicated by markedly elevated transaminases. (Hepatology guidelines) 1
• Phosphatidylethanol testing can be used to verify adherence when self‑report is unreliable. (Hepatology guidelines) 1

Blood‑Pressure Management

• Stage 2 hypertension mandates immediate initiation of dual antihypertensive therapy; lifestyle measures alone are insufficient. (American Heart Association) 3
• First‑line regimen: a single‑pill combination of an ACE‑inhibitor or ARB + a long‑acting dihydropyridine calcium‑channel blocker (e.g., perindopril/amlodipine). (American College of Endocrinology) 4
• Target office BP < 130/80 mmHg within 3 months of therapy start. (American College of Endocrinology; American Heart Association) [4][3]
• If the 3‑month target is not reached, add a thiazide‑type diuretic (chlorthalidone or hydrochlorothiazide) to create triple therapy. (American College of Endocrinology) 4

Dyslipidemia Management

• High‑intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) should be started regardless of baseline lipid values. (American College of Endocrinology) 6
• Statins are safe in patients with non‑alcoholic or alcoholic fatty liver disease and may improve liver enzymes without increasing hepatotoxicity risk. (American College of Endocrinology; Asian Pacific Association for the Study of the Liver) [6][7]
• Patients with multiple cardiovascular risk factors (young age, smoking, hypertension, dyslipidemia) are classified as “high CV risk”; LDL‑C goal < 100 mg/dL. (American College of Endocrinology) 6
• Non‑HDL‑C goal < 130 mg/dL; triglyceride goal < 150 mg/dL; total‑cholesterol goal < 200 mg/dL. (American College of Endocrinology) 6
• If LDL‑C remains above target after 4–6 weeks of high‑intensity statin, add ezetimibe 10 mg daily. (American College of Cardiology) 8
• If LDL‑C is still above goal after statin + ezetimibe, consider a PCSK9 inhibitor (evolocumab or alirocumab) or bempedoic acid. (American College of Cardiology) 8
• For triglycerides 135–499 mg/dL, add icosapent ethyl 4 g/day as an adjunct to statin therapy to lower cardiovascular risk. (American College of Endocrinology) 6
• Dietary lipid recommendations: saturated fat < 7 % of total energy, dietary cholesterol < 200 mg/day, eliminate trans fats. (American College of Endocrinology) 6
• Sodium intake should be limited to ≤ 2 400 mg/day. (American College of Endocrinology) 4

Lifestyle Interventions

• Adopt a DASH‑style dietary pattern rich in fruits, vegetables, low‑fat dairy, whole grains, and plant‑based proteins while limiting saturated fat, cholesterol, and added sugars. (Canadian Cardiovascular Society) 9
• Aim for dietary fiber intake of at least 25 g/day (Mediterranean‑style emphasis on vegetables, fruits, whole grains, nuts). (American College of Endocrinology) 6
• Engage in 30–60 minutes of moderate‑intensity aerobic exercise on 5–7 days per week; higher intensities do not provide additional BP benefit. (Canadian Cardiovascular Society) 9
• Target weight loss of ≥ 4.5 kg to improve blood pressure, glycemic control, and liver enzymes. (Canadian Cardiovascular Society) 9
• After liver enzymes normalize, limit alcohol to ≤ 2 standard drinks per day for men if complete abstinence cannot be maintained long‑term. (Canadian Cardiovascular Society) 9

Monitoring & Follow‑Up

• Re‑measure fasting lipid panel 4–6 weeks after initiating statin therapy to assess response and guide escalation. (American College of Endocrinology) 6
• Repeat lipid testing every 3–6 months until goals are met, then annually. (American College of Endocrinology) 6
• Check AST, ALT, and full liver panel 4 weeks after alcohol abstinence to evaluate improvement. (Asian Pacific Association for the Study of the Liver; Hepatology guidelines) [7][1]
• Calculate FIB‑4 score (Age × AST / [Platelet × √ALT]); refer to hepatology if FIB‑4 > 1.3. (American College of Endocrinology) 4

Cardiovascular Risk Reduction

• Aspirin for primary prevention should be initiated only after blood pressure is controlled to < 150/90 mmHg; then low‑dose aspirin 75–81 mg daily may be considered in high‑risk individuals. (Guideline not cited in non‑Praxis source; omitted)

Critical Pitfalls (Non‑Redundant)

• Do not delay combination antihypertensive therapy while attempting lifestyle changes alone; stage 2 hypertension requires immediate dual pharmacotherapy. (American Heart Association) 3
• Do not withhold statin therapy because of baseline transaminase elevations; statins are generally safe in fatty liver disease and may improve liver enzymes. (American College of Endocrinology; Asian Pacific Association for the Study of the Liver) [6][7]
• Do not postpone hepatology referral if liver enzymes fail to improve after 3 months of abstinence or if FIB‑4 indicates significant fibrosis risk. (American College of Endocrinology; Asian Pacific Association for the Study of the Liver) [4][7]